Cargando…
THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes
Disclosure: A. Taiwo: None. H. Thakker: None. J. Maschek: None. J. Cox: None. S. Summers: Owner/Co-Owner; Self; Centaurus Therapeutics. D. Jalal: None. W. Sivitz: None. A. Dokun: None. B. Chaurasia: None. Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by steatosis at an early...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554222/ http://dx.doi.org/10.1210/jendso/bvad114.584 |
_version_ | 1785116360889597952 |
---|---|
author | Taiwo, Adeyinka Thakker, Himani Maschek, John Cox, James Summers, Scott Jalal, Diana Sivitz, William Dokun, Ayotunde Chaurasia, Bhagirath |
author_facet | Taiwo, Adeyinka Thakker, Himani Maschek, John Cox, James Summers, Scott Jalal, Diana Sivitz, William Dokun, Ayotunde Chaurasia, Bhagirath |
author_sort | Taiwo, Adeyinka |
collection | PubMed |
description | Disclosure: A. Taiwo: None. H. Thakker: None. J. Maschek: None. J. Cox: None. S. Summers: Owner/Co-Owner; Self; Centaurus Therapeutics. D. Jalal: None. W. Sivitz: None. A. Dokun: None. B. Chaurasia: None. Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by steatosis at an early stage, which can progress over the years to nonalcoholic steatohepatitis (NASH) and cirrhosis. Steatosis is composed of various lipid species which is derived from influx of monounsaturated and polyunsaturated fatty acids, saturated fats, into the liver caused by peripheral lipolysis in adipocytes and de novo lipogenesis. It is estimated that 20-30% patients with NAFLD will progress to NASH. Hepatic lipotoxicity and inflammation are two key factors that drive the progression of NAFLD to NASH. The presence of NASH increases the risk of cardiovascular events, cirrhosis, hepatocellular cancer and non-liver malignancies. Objective: To determine the association of lipid species with NAFLD in individuals with Type 1 diabetes. Study Design: Thirty individuals with Type 1 diabetes were recruited from our diabetes Clinic at University of Iowa Hospital & Clinics. Participants in this cross-sectional study were categorized into two groups based on the results of a FibroScan, an elastography technique that quantifies liver fat and stiffness. Classification as cases (n = 16) or controls (n = 14) was assigned based on the presence or absence of evidence for NAFLD respectively. The participants came in for a single visit where fasting plasma was drawn for lipidomics analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). In total thirty-three lipid species belonging to four different lipid classes: sphingolipids (dihydroceramides, ceramides, dihydrosphingomyelin, sphingomyelin, hexosylceramide), diacylglycerol, phosphatidylcholine and triacylglycerols were analyzed via targeted lipidomics. Results: The BMI was significantly higher in the cases than controls (P = 0.002) and the cases used significantly higher 24 hr insulin doses than controls (P = 0.004). The cases displayed significantly higher circulating levels of total ceramides (p=0.02), diacylglycerol (P= 0.0003) and triacylglycerols (P=0.0003). The two groups displayed similar levels of hexosylceramide, dihydrosphingomyelin, sphingomyelin and phosphatidylcholine. Similar to previous findings numerous sphingolipid species, diacylglycerol and triacylglycerols were found to be positively correlated with BMI. In addition, they were found to be positively correlated with 24hrs insulin dose. Importantly, total circulating dihydroceramide, ceramide, diacylglycerol and triacylglycerols levels were significantly corelated with steatosis score (P = <0.05). None of the lipid species correlated with the fibrosis score. Conclusion: These results suggest that Type 1 diabetes individuals with NAFLD have a higher BMI and display elevated circulating levels of dihydroceramides, ceramides, diacylglycerol and triacylglycerols that are strongly associated with the development of fatty liver disease. Presentation: Thursday, June 15, 2023 |
format | Online Article Text |
id | pubmed-10554222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105542222023-10-06 THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes Taiwo, Adeyinka Thakker, Himani Maschek, John Cox, James Summers, Scott Jalal, Diana Sivitz, William Dokun, Ayotunde Chaurasia, Bhagirath J Endocr Soc Cardiovascular Endocrinology Disclosure: A. Taiwo: None. H. Thakker: None. J. Maschek: None. J. Cox: None. S. Summers: Owner/Co-Owner; Self; Centaurus Therapeutics. D. Jalal: None. W. Sivitz: None. A. Dokun: None. B. Chaurasia: None. Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by steatosis at an early stage, which can progress over the years to nonalcoholic steatohepatitis (NASH) and cirrhosis. Steatosis is composed of various lipid species which is derived from influx of monounsaturated and polyunsaturated fatty acids, saturated fats, into the liver caused by peripheral lipolysis in adipocytes and de novo lipogenesis. It is estimated that 20-30% patients with NAFLD will progress to NASH. Hepatic lipotoxicity and inflammation are two key factors that drive the progression of NAFLD to NASH. The presence of NASH increases the risk of cardiovascular events, cirrhosis, hepatocellular cancer and non-liver malignancies. Objective: To determine the association of lipid species with NAFLD in individuals with Type 1 diabetes. Study Design: Thirty individuals with Type 1 diabetes were recruited from our diabetes Clinic at University of Iowa Hospital & Clinics. Participants in this cross-sectional study were categorized into two groups based on the results of a FibroScan, an elastography technique that quantifies liver fat and stiffness. Classification as cases (n = 16) or controls (n = 14) was assigned based on the presence or absence of evidence for NAFLD respectively. The participants came in for a single visit where fasting plasma was drawn for lipidomics analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). In total thirty-three lipid species belonging to four different lipid classes: sphingolipids (dihydroceramides, ceramides, dihydrosphingomyelin, sphingomyelin, hexosylceramide), diacylglycerol, phosphatidylcholine and triacylglycerols were analyzed via targeted lipidomics. Results: The BMI was significantly higher in the cases than controls (P = 0.002) and the cases used significantly higher 24 hr insulin doses than controls (P = 0.004). The cases displayed significantly higher circulating levels of total ceramides (p=0.02), diacylglycerol (P= 0.0003) and triacylglycerols (P=0.0003). The two groups displayed similar levels of hexosylceramide, dihydrosphingomyelin, sphingomyelin and phosphatidylcholine. Similar to previous findings numerous sphingolipid species, diacylglycerol and triacylglycerols were found to be positively correlated with BMI. In addition, they were found to be positively correlated with 24hrs insulin dose. Importantly, total circulating dihydroceramide, ceramide, diacylglycerol and triacylglycerols levels were significantly corelated with steatosis score (P = <0.05). None of the lipid species correlated with the fibrosis score. Conclusion: These results suggest that Type 1 diabetes individuals with NAFLD have a higher BMI and display elevated circulating levels of dihydroceramides, ceramides, diacylglycerol and triacylglycerols that are strongly associated with the development of fatty liver disease. Presentation: Thursday, June 15, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10554222/ http://dx.doi.org/10.1210/jendso/bvad114.584 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Cardiovascular Endocrinology Taiwo, Adeyinka Thakker, Himani Maschek, John Cox, James Summers, Scott Jalal, Diana Sivitz, William Dokun, Ayotunde Chaurasia, Bhagirath THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes |
title | THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes |
title_full | THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes |
title_fullStr | THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes |
title_full_unstemmed | THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes |
title_short | THU586 Lipid Species In Non-alcoholic Fatty Liver Disease (NAFLD) In Type 1 Diabetes |
title_sort | thu586 lipid species in non-alcoholic fatty liver disease (nafld) in type 1 diabetes |
topic | Cardiovascular Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554222/ http://dx.doi.org/10.1210/jendso/bvad114.584 |
work_keys_str_mv | AT taiwoadeyinka thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes AT thakkerhimani thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes AT maschekjohn thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes AT coxjames thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes AT summersscott thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes AT jalaldiana thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes AT sivitzwilliam thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes AT dokunayotunde thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes AT chaurasiabhagirath thu586lipidspeciesinnonalcoholicfattyliverdiseasenafldintype1diabetes |